MX2017008462A - Metodos para utilizar oligonucleotidos antisentido para smad7. - Google Patents

Metodos para utilizar oligonucleotidos antisentido para smad7.

Info

Publication number
MX2017008462A
MX2017008462A MX2017008462A MX2017008462A MX2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A MX 2017008462 A MX2017008462 A MX 2017008462A
Authority
MX
Mexico
Prior art keywords
smad7 antisense
methods
patient
antisense oligonucleotides
ibd
Prior art date
Application number
MX2017008462A
Other languages
English (en)
Inventor
andrew smith Scott
Li Xiaobin
ROSSITER Guillermo
L Martin Philippe
R Dewacker Seth
Usiskin Keith
Allan Cline Gary
Original Assignee
Celgene Alpine Invest Company Ii Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Alpine Invest Company Ii Llc filed Critical Celgene Alpine Invest Company Ii Llc
Publication of MX2017008462A publication Critical patent/MX2017008462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen métodos para tratar la enfermedad intestinal inflamatoria (IBD) en un paciente que tiene IBD utilizando oligonucleótidos antisentido para SMAD7.
MX2017008462A 2014-12-26 2015-12-23 Metodos para utilizar oligonucleotidos antisentido para smad7. MX2017008462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462097012P 2014-12-26 2014-12-26
US201562235269P 2015-09-30 2015-09-30
PCT/US2015/000269 WO2016105516A1 (en) 2014-12-26 2015-12-23 Methods of using smad7 antisense oligonucleotides

Publications (1)

Publication Number Publication Date
MX2017008462A true MX2017008462A (es) 2018-02-26

Family

ID=56151259

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008462A MX2017008462A (es) 2014-12-26 2015-12-23 Metodos para utilizar oligonucleotidos antisentido para smad7.

Country Status (17)

Country Link
US (1) US20190112608A1 (es)
EP (1) EP3237018A4 (es)
JP (1) JP2018502107A (es)
KR (1) KR20170105529A (es)
CN (1) CN107405413A (es)
AU (1) AU2015371325A1 (es)
BR (1) BR112017013765A2 (es)
CA (1) CA2971583A1 (es)
CL (1) CL2017001701A1 (es)
CO (1) CO2017007383A2 (es)
EA (1) EA201791471A1 (es)
EC (1) ECSP17040003A (es)
IL (1) IL253023A0 (es)
MA (1) MA41271A (es)
MX (1) MX2017008462A (es)
SG (1) SG11201705179TA (es)
WO (1) WO2016105516A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170069262A (ko) 2014-10-17 2017-06-20 노그라 파마 리미티드 Smad7 안티센스 올리고뉴클레오티드로 대상체를 치료하기 위한 방법 및 조성물
EP3420082A4 (en) 2016-02-23 2019-10-16 Celgene Alpine Investment Company II, LLC METHOD FOR THE TREATMENT OF DARM FIBROSIS USING SMAD7 INHIBITION
WO2018111323A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Methods and ingestible devices for the regio-specific release of smad7 inhibitors at the site of gastrointestinal tract disease
CA3045472A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
JOP20200280A1 (ar) * 2018-05-09 2020-11-05 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير الوراثي عن fxi
TWI833770B (zh) 2018-06-27 2024-03-01 美商Ionis製藥公司 用於減少 lrrk2 表現之化合物及方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613751B2 (en) * 2000-02-23 2003-09-02 The Regents Of The University Of California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
JP2005529152A (ja) * 2002-05-17 2005-09-29 プロテイン デザイン ラブス インコーポレイティド 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
EP2059234B1 (en) * 2006-09-08 2011-11-02 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
US20100035850A1 (en) * 2006-11-17 2010-02-11 Shire Development Inc. Method of treatment for inflammatory bowel disease
WO2010020593A1 (en) * 2008-08-18 2010-02-25 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
RU2739302C2 (ru) * 2008-11-13 2020-12-22 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
TR201000680A2 (tr) * 2010-01-29 2011-08-22 B�Lg�� Mahmut Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler
JP6389122B2 (ja) * 2011-09-15 2018-09-12 ノグラ ファーマ リミテッド 抗ｓｍａｄ７治療に対する応答性をモニターするための方法
AU2015257589A1 (en) * 2014-05-09 2016-11-24 Nogra Pharma Limited Methods for treating inflammatory bowel disease
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US20170247695A1 (en) * 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides

Also Published As

Publication number Publication date
EP3237018A1 (en) 2017-11-01
IL253023A0 (en) 2017-08-31
CO2017007383A2 (es) 2018-01-05
WO2016105516A1 (en) 2016-06-30
CL2017001701A1 (es) 2018-04-06
WO2016105516A8 (en) 2017-07-06
BR112017013765A2 (pt) 2018-02-27
ECSP17040003A (es) 2017-10-31
CN107405413A (zh) 2017-11-28
EP3237018A4 (en) 2018-07-11
KR20170105529A (ko) 2017-09-19
JP2018502107A (ja) 2018-01-25
AU2015371325A1 (en) 2017-07-13
SG11201705179TA (en) 2017-07-28
US20190112608A1 (en) 2019-04-18
MA41271A (fr) 2017-10-31
EA201791471A1 (ru) 2017-12-29
CA2971583A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
MX2017008462A (es) Metodos para utilizar oligonucleotidos antisentido para smad7.
ZA202208792B (en) Methods of treating and preventing graft versus host disease
EA201790398A1 (ru) Способы лечения заболевания печени
MX2021010672A (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer.
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CL2017002774A1 (es) Secuencias de uricasa mejorada y métodos de tratamiento
MX2015013703A (es) Mitigacion e inversion de la fibrosis e inflamacion mediante la inhibicion de la funcion de tl1a y vias de señalizacion relacionadas.
PH12017500392A1 (en) Medical treatments based on anamorelin
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
GB201022049D0 (en) Methods
RU2014145910A (ru) Способы воздействия на экспрессию гена APOE
MX2014008194A (es) Cefovecina util en el tratamiento de la enfermedad de lyme.
RU2014143385A (ru) Способы воздействия на экспрессию гена TP53
RU2014148879A (ru) Способы воздействия на экспрессию гена PRP
RU2014148258A (ru) Способы воздействия на экспрессию гена ADA
RU2014148877A (ru) Способы воздействия на экспрессию гена BRCA1
RU2014144093A (ru) Способы воздействия на экспрессию гена CRE
RU2014142752A (ru) Способы воздействия на экспрессию гена лактазы
RU2014146616A (ru) Способы воздействия на экспрессию гена SNRPN
RU2014144700A (ru) Способы воздействия на экспрессию гена UBE3А
RU2014142755A (ru) Способы воздействия на экспрессию гена CYP17
RU2014142756A (ru) Способы воздействия на экспрессию гена D4DR
RU2014144094A (ru) Способы воздействия на экспрессию гена CREBBP
RU2014142757A (ru) Способ воздействия на экспрессию гена TCF